Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway.

Thurston G, Daly C.

Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006550. doi: 10.1101/cshperspect.a006650. Review.

2.

Expression and function of Angiopoietins and their tie receptors in human basophils and mast cells.

Prevete N, Staiano RI, Granata F, Detoraki A, Necchi V, Ricci V, Triggiani M, De Paulis A, Marone G, Genovese A.

J Biol Regul Homeost Agents. 2013 Jul-Sep;27(3):827-39.

PMID:
24152847
3.

Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium.

Yuan HT, Khankin EV, Karumanchi SA, Parikh SM.

Mol Cell Biol. 2009 Apr;29(8):2011-22. doi: 10.1128/MCB.01472-08. Epub 2009 Feb 17. Erratum in: Mol Cell Biol. 2009 Jun;29(12):3451.

4.

Angiopoietin-2: development of inhibitors for cancer therapy.

Hu B, Cheng SY.

Curr Oncol Rep. 2009 Mar;11(2):111-6. Review.

5.

Enhanced expression of angiopoietin-2 and the Tie2 receptor but not angiopoietin-1 or the Tie1 receptor in a rat model of myocardial infarction.

Shyu KG, Liang YJ, Chang H, Wang BW, Leu JG, Kuan P.

J Biomed Sci. 2004 Mar-Apr;11(2):163-71.

PMID:
14966366
6.

Tie1 controls angiopoietin function in vascular remodeling and inflammation.

Korhonen EA, Lampinen A, Giri H, Anisimov A, Kim M, Allen B, Fang S, D'Amico G, Sipilä TJ, Lohela M, Strandin T, Vaheri A, Ylä-Herttuala S, Koh GY, McDonald DM, Alitalo K, Saharinen P.

J Clin Invest. 2016 Sep 1;126(9):3495-510. doi: 10.1172/JCI84923. Epub 2016 Aug 22.

7.

The Tie2 receptor antagonist angiopoietin 2 facilitates vascular inflammation in systemic lupus erythematosus.

Kümpers P, David S, Haubitz M, Hellpap J, Horn R, Bröcker V, Schiffer M, Haller H, Witte T.

Ann Rheum Dis. 2009 Oct;68(10):1638-43. doi: 10.1136/ard.2008.094664. Epub 2008 Oct 17.

PMID:
18930996
8.

Genetic dissection of tie pathway in mouse lymphatic maturation and valve development.

Shen B, Shang Z, Wang B, Zhang L, Zhou F, Li T, Chu M, Jiang H, Wang Y, Qiao T, Zhang J, Sun W, Kong X, He Y.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1221-30. doi: 10.1161/ATVBAHA.113.302923. Epub 2014 Apr 24.

9.

The yin, the yang, and the angiopoietin-1.

Saharinen P, Alitalo K.

J Clin Invest. 2011 Jun;121(6):2157-9. doi: 10.1172/JCI58196. Epub 2011 May 23.

10.

Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2.

Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, Stewart DJ.

Cardiovasc Res. 2001 Feb 16;49(3):659-70.

PMID:
11166279
11.

Tie1 regulates the Tie2 agonistic role of angiopoietin-2 in human lymphatic endothelial cells.

Song SH, Kim KL, Lee KA, Suh W.

Biochem Biophys Res Commun. 2012 Mar 9;419(2):281-6. doi: 10.1016/j.bbrc.2012.02.009. Epub 2012 Feb 10.

PMID:
22342979
12.

Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels.

Falcón BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM.

Am J Pathol. 2009 Nov;175(5):2159-70. doi: 10.2353/ajpath.2009.090391. Epub 2009 Oct 8.

13.

Ligand oligomerization state controls Tie2 receptor trafficking and angiopoietin-2-specific responses.

Pietilä R, Nätynki M, Tammela T, Kangas J, Pulkki KH, Limaye N, Vikkula M, Koh GY, Saharinen P, Alitalo K, Eklund L.

J Cell Sci. 2012 May 1;125(Pt 9):2212-23. doi: 10.1242/jcs.098020. Epub 2012 Feb 22.

14.

Angiopoietin-2-driven vascular remodeling in airway inflammation.

Tabruyn SP, Colton K, Morisada T, Fuxe J, Wiegand SJ, Thurston G, Coyle AJ, Connor J, McDonald DM.

Am J Pathol. 2010 Dec;177(6):3233-43. doi: 10.2353/ajpath.2010.100059. Epub 2010 Oct 15.

15.

Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD.

Science. 1997 Jul 4;277(5322):55-60.

16.

Expression of angiopoietin-1, angiopoietin-2, and Tie2 genes in normal ovary with corpus luteum and in ovarian cancer.

Hata K, Udagawa J, Fujiwaki R, Nakayama K, Otani H, Miyazaki K.

Oncology. 2002;62(4):340-8.

PMID:
12138242
17.

Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.

Daly C, Eichten A, Castanaro C, Pasnikowski E, Adler A, Lalani AS, Papadopoulos N, Kyle AH, Minchinton AI, Yancopoulos GD, Thurston G.

Cancer Res. 2013 Jan 1;73(1):108-18. doi: 10.1158/0008-5472.CAN-12-2064. Epub 2012 Nov 13.

18.

Angiopoietins in angiogenesis.

Fagiani E, Christofori G.

Cancer Lett. 2013 Jan 1;328(1):18-26. doi: 10.1016/j.canlet.2012.08.018. Epub 2012 Aug 23. Review.

PMID:
22922303
19.

Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.

Stratmann A, Acker T, Burger AM, Amann K, Risau W, Plate KH.

Int J Cancer. 2001 Feb 1;91(3):273-82.

20.

Differential response of lymphatic, venous and arterial endothelial cells to angiopoietin-1 and angiopoietin-2.

Nguyen VP, Chen SH, Trinh J, Kim H, Coomber BL, Dumont DJ.

BMC Cell Biol. 2007 Mar 6;8:10.

Supplemental Content

Support Center